Photo of Carmelo Nucera, MD, PhD

Carmelo Nucera, MD, PhD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-5964


cnucera@bidmc.harvard.edu

Photo of Carmelo Nucera, MD, PhD

Beth Israel Deaconess Medical Center
Phone: (617) 667-5964


cnucera@bidmc.harvard.edu

Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Carmelo Nucera, MD, PhD but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members

Carmelo Nucera, MD, PhD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Associate Professor , Pathology, Harvard Medical School
  • Associate Professor, Pathology, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

As a Principal Investigator and Faculty Member at HMS, I have successfully advanced many basic and translational projects and collaborations, and will continue to do so thanks to major grants from the NIH and NCI, along with local and international awards including the Harold Dvorak, Van Meter, the ITOG, the Guido Berlucchi, and the Anassilaos awards.

I am driven, as well as my research team, by an intense desire to make important scientific contributions that will benefit or even cure patients suffering from aggressive tumors. I have first-hand experience with patients with serious or fatal diseases, including cancer, which has shaped my understanding of the fundamental need for humane, ethical, and passionate research.

I am currently focused on identifying new prognostic biomarkers (including non-coding RNAs), validating new therapeutic targets against aggressive advanced thyroid tumors, and unravelling drug resistance mechanisms in advanced thyroid tumors.

My research team/lab work will foster development of innovative therapies for advanced thyroid tumors that are refractory to current treatments. We have extensive expertise, a strong multidisciplinary team expert in the field of thyroid cancer microenvironment, mouse models, lncRNAs, the transcriptome, and human thyroid tissue collection to ensure the success of the research mission.

My goal is to synergize my translational research into thyroid/endocrine cancer and biomarkers with clinical trials at leading biomedical centers, while developing improved discovery and innovation techniques.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Iesato A, Li S, Sadow PM, Abbasian M, Nazarian A, Lawler J, Nucera C. The tyrosine kinase inhibitor lenvatinib inhibits anaplastic thyroid carcinoma growth by targeting pericytes in the tumor microenvironment. Thyroid 2023. PubMed
  • Lee H, Krishnan V, Wirth LJ, Nucera C, Sadow PM, Venturina M, Mita A, Sacks W. Case Report of CCDC149-ALK fusion: a novel genetic alteration and a clinically relevant target in metastatic papillary thyroid carcinoma. Thyroid 2022. PubMed
  • Valvo V, Iesato A, Kavanagh TR, Priolo C, Zsengeller Z, Pontecorvi A, Stillman IE, Burke SD, Liu X, Nucera C. Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in Papillary Thyroid Carcinoma. Thyroid 2021; 31:1335-1358. PubMed
  • Iesato A, Li S, Roti G, Hacker MR, Fischer AH, Nucera C. Lenvatinib targets PDGFR-β pericytes and inhibits synergy with thyroid carcinoma cells: novel translational insights. J Clin Endocrinol Metab 2021. PubMed
  • Iesato A, Nucera C. Role of Regulatory Non-Coding RNAs in Aggressive Thyroid Cancer: Prospective Applications of Neural Network Analysis. Molecules 2021. PubMed
  • Iesato A, Nucera C. Tumor Microenvironment-Associated Pericyte Populations May Impact Therapeutic Response in Thyroid Cancer. Adv Exp Med Biol 2021; 1329:253-269. PubMed
  • Valvo V, Nucera C. Coding Molecular Determinants of Thyroid Cancer Development and Progression. Endocrinol. Metab. Clin. North Am. 2019; 48:37-59. PubMed
  • McGonagle ER, Nucera C. Clonal Reconstruction of Thyroid Cancer: An Essential Strategy for Preventing Resistance to Ultra-Precision Therapy. Front Endocrinol (Lausanne) 2019; 10:468. PubMed
  • Prete A, Lo AS, Sadow PM, Bhasin SS, Antonello ZA, Vodopivec DM, Ullas S, Sims JN, Clohessy J, Dvorak AM, Sciuto T, Bhasin M, Murphy-Ullrich JE, Lawler J, Karumanchi SA, Nucera C. Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis. Clin Cancer Res 2018. PubMed
  • Antonello ZA, Hsu N, Bhasin M, Roti G, Joshi M, Van Hummelen P, Ye E, Lo AS, Karumanchi SA, Bryke CR, Nucera C. Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF. 2017; 8:84743-84760. PubMed
  • Mehrzad R, Nishino M, Nucera C, Dias-Santagata D, Hennessey JV, Hasselgren PO. Invasive follicular variant of papillary thyroid cancer harboring the NRAS mutation Q61K and presenting with bone metastasis-A case report. Int J Surg Case Rep 2017; 38:180-184. PubMed
  • Daniell K, Nucera C. Effect of the micronutrient iodine in thyroid carcinoma angiogenesis. Aging (Albany NY) 2016; 8:3180-3184. PubMed
  • Nucera C. Evolution of resistance to thyroid cancer therapy. Aging (Albany NY) 2016; 8:1576-7. PubMed
  • Sadow PM, Dias-Santagata D, Zheng Z, Lin DT, Le LP, Nucera C. Identification of insertions in PTEN and TP53 in anaplastic thyroid carcinoma with angiogenic brain metastasis. Endocr. Relat. Cancer 2015; 22:L23-8. PubMed
  • Duquette M, Sadow PM, Husain A, Sims JN, Antonello ZA, Fischer AH, Song C, Castellanos-Rizaldos E, Makrigiorgos GM, Kurebayashi J, Nose V, Van Hummelen P, Bronson RT, Vinco M, Giordano TJ, Dias-Santagata D, Pandolfi PP, Nucera C. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. 2015. PubMed
  • Husain A, Hu N, Sadow PM, Nucera C. Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E). Cancer Lett 2015. PubMed
  • Smith N, Nucera C. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations. J Clin Endocrinol Metab 2015; 100:35-42. PubMed
  • Sadow PM, Priolo C, Nanni S, Karreth FA, Duquette M, Martinelli R, Husain A, Clohessy J, Kutzner H, Mentzel T, Carman CV, Farsetti A, Henske EP, Palescandolo E, Macconaill LE, Chung S, Fadda G, Lombardi CP, De Angelis AM, Durante O, Parker JA, Pontecorvi A, Dvorak HF, Fletcher C, Pandolfi PP, Lawler J, Nucera C. Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment. Journal of the National Cancer Institute 2014. PubMed
  • Nucera C. Targeting thyroid cancer microenvironment: basic research and clinical applications. Front Endocrinol (Lausanne) 2013; 4:167. PubMed
  • Duquette M, Sadow PM, Lawler J, Nucera C. Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment. Front Endocrinol (Lausanne) 2013; 4:189. PubMed
  • Bellelli R, Castellone MD, Garcia-Rostan G, Ugolini C, Nucera C, Sadow PM, Nappi TC, Salerno P, Cantisani MC, Basolo F, Gago TA, Salvatore G, Santoro M. FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. Endocr. Relat. Cancer 2012; 19:695-710. PubMed
  • Shaik S, Nucera C, Inuzuka H, Gao D, Garnaas M, Frechette G, Harris L, Wan L, Fukushima H, Husain A, Nose V, Fadda G, Sadow PM, Goessling W, North T, Lawler J, Wei W. SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med 2012; 209:1289-307. PubMed
  • Nehs MA, Nucera C, Nagarkatti SS, Sadow PM, Morales-Garcia D, Hodin RA, Parangi S. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology 2012; 153:985-94. PubMed
  • Nucera C, Pontecorvi A. Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer? Front Endocrinol (Lausanne) 2012; 3:33. PubMed
  • Nucera C, Lawler J, Parangi S. BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res 2011; 71:2417-22. PubMed
  • Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS, Bollag GE, Lawler J, Hodin RA, Parangi S. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist 2011; 16:296-309. PubMed
  • Nucera C, Lawler J, Hodin R, Parangi S. The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? 2010; 1:751-6. PubMed
  • Nehs MA, Nagarkatti S, Nucera C, Hodin RA, Parangi S. Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. Surgery 2010; 148:1154-62; discussion 1162. PubMed
  • Nucera C, Muzzi P, Tiveron C, Farsetti A, La Regina F, Foglio B, Shih SC, Moretti F, Della Pietra L, Mancini F, Sacchi A, Trimarchi F, Vercelli A, Pontecorvi A. Maternal thyroid hormones are transcriptionally active during embryo-foetal development: results from a novel transgenic mouse model. J Cell Mol Med 2010; 14:2417-35. PubMed
  • Mekel M, Nucera C, Hodin RA, Parangi S. Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. Am J Surg 2010; 200:136-43. PubMed
  • Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, Finn S, Jarzab B, Hodin RA, Pontecorvi A, Nose V, Lawler J, Parangi S. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A 2010; 107:10649-54. PubMed
  • Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463:899-905. PubMed
  • Nucera C, Nehs MA, Mekel M, Zhang X, Hodin R, Lawler J, Nose V, Parangi S. A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid 2009; 19:1077-84. PubMed
  • Nucera C,Eeckhoute J,Finn S,Carroll JS,Ligon AH,Priolo C,Fadda G,Toner M,Sheils O,Attard M,Pontecorvi A,Nose V,Loda M,Brown M. FOXA1 Is a Potential Oncogene in Anaplastic Thyroid Carcinoma. Clin Cancer Res 2009; 15:3680-9. PubMed
  • Nucera C, Goldfarb M, Hodin R, Parangi S. Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta 2009; 1795:152-61. PubMed
  • Nucera C, Vaccaro M, Moleti M, Priolo C, Tortorella G, Angioni A, Ientile R, Violi MA, Loda M, Trimarchi F, Vermiglio F. antiphospholipid antibodies syndrome associated with hyperhomocysteinemia related to MTHFR Gene C677T and A1298C heterozygous mutations in a young man with idiopathic hypoparathyroidism (DiGeorge syndrome). J Clin Endocrinol Metab 2006; 91:2021-6. PubMed
  • Moleti M, Mattina F, Salamone I, Violi MA, Nucera C, Baldari S, Lo Schiavo MG, Regalbuto C, Trimarchi F, Vermiglio F. Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of graves' ophthalmopathy. Thyroid 2003; 13:653-8. PubMed
  • Kovach AE, Nucera C, Lam QT, Nguyen A, Dias-Santagata D, Sadow PM. Genomic and immunohistochemical analysis in human adrenal cortical neoplasia reveal beta-catenin mutations as potential prognostic biomarker. Discoveries (Craiova) . PubMed
Hide
Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Carmelo Nucera, MD, PhD but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members